Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04543591
Registration number
NCT04543591
Ethics application status
Date submitted
17/08/2020
Date registered
10/09/2020
Date last updated
3/05/2024
Titles & IDs
Public title
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
Query!
Scientific title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Ravulizumab in Adult and Adolescent Participants Who Have Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplant (HSCT)
Query!
Secondary ID [1]
0
0
ALXN1210-TMA-313
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Thrombotic Microangiopathy
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Ravulizumab
Other interventions - Placebo
Other interventions - Best supportive care
Experimental: Ravulizumab - In Stage 1, all participants will receive open-label ravulizumab plus Best Supportive Care (BSC).
In Stage 2, participants will receive blinded ravulizumab plus Best Supportive Care (BSC).
Placebo Comparator: Placebo - In Stage 2, participants randomized to the placebo arm will receive matching placebo plus BSC.
Other interventions: Ravulizumab
Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
Other interventions: Placebo
Matching placebo
Other interventions: Best supportive care
Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
TMA Response
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
26 weeks (treatment period)
Query!
Secondary outcome [1]
0
0
Time To TMA Response
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
26 weeks (treatment period)
Query!
Secondary outcome [2]
0
0
Change from Baseline in eGFR
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
26 weeks (treatment period)
Query!
Secondary outcome [3]
0
0
Overall Survival
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
26 weeks (treatment period)
Query!
Secondary outcome [4]
0
0
Non-relapse Mortality
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
26 weeks (treatment period)
Query!
Secondary outcome [5]
0
0
Hematologic Response
Query!
Assessment method [5]
0
0
Hematologic Response as assessed by blood tests to measure lactate dehydrogenase (LDH) and platelet count.
(1) If baseline platelet count = 50000/mm3, the following criteria must be met:
- Absolute platelet count > 50,000/mm3 without platelet transfusion support during the prior 7 days [or]
If baseline platelet count > 50,000/mm3, the following criteria must be met:
- = 50% increase in platelet count compared to baseline value without platelet transfusion support during the prior 7 days
2) Normalization of LDH and absence of schistocytes
Query!
Timepoint [5]
0
0
26 weeks (treatment period)
Query!
Eligibility
Key inclusion criteria
1. 12 years of age or older at time of consent/assent.
2. Received HSCT within the past 12 months
3. Diagnosis of TMA that persists for at least 72 hours despite initial management
4. A TMA diagnosis based on meeting the select criteria during the Screening Period
and/or <=14 days prior to the Screening Period.
5. Body weight = 30 kilograms at Screening or =7 days prior to the start of the Screening
Period (date of consent).
6. Female participants of childbearing potential and male participants with female
partners of childbearing potential must use highly effective contraception.
7. Participants must be vaccinated against meningococcal infections if clinically
feasible. Participants who cannot receive meningococcal vaccine should receive
antibiotic prophylaxis.
8. Participants or their legally authorized representative must be capable of giving
signed informed consent or assent
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Thrombotic thrombocytopenic purpura (TTP) evidenced by ADAMTS13 deficiency
2. Shiga toxin producing Escherichia coli infection
3. Positive direct Coombs test.
4. Clinical diagnosis of disseminated intravascular coagulation (DIC).
5. Known bone marrow/graft failure.
6. Diagnosis of veno-occlusive disease.
7. Human immunodeficiency virus (HIV) infection.
8. Unresolved meningococcal disease.
9. Presence of sepsis requiring vasopressor support.
10. Pregnancy or breastfeeding.
11. Previously or currently treated with a complement inhibitor.
12. Respiratory failure requiring mechanical ventilation.
13. Acute and/or chronic heart failure.
14. Participation in an interventional treatment study of any therapy for TMA.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
10/12/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/07/2025
Query!
Actual
Query!
Sample size
Target
106
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Research Site - Adelaide
Query!
Recruitment hospital [2]
0
0
Research Site - Murdoch
Query!
Recruitment hospital [3]
0
0
Research Site - Parkville
Query!
Recruitment hospital [4]
0
0
Research Site - Westmead
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [3]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [4]
0
0
2145 - Westmead
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kansas
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Kentucky
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Utah
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Washington
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Wisconsin
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Antwerpen
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Brugge
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Bruxelles
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Chênée
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Leuven
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Yvoir
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Barretos
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Cerqueira César
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Florianópolis
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Jaú
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
Porto Alegre
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
Rio de Janeiro
Query!
Country [30]
0
0
Brazil
Query!
State/province [30]
0
0
Salvador
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
Sao Jose Do Rio Preto
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Sao Paulo
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
São Paulo
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Alberta
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Ontario
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Quebec
Query!
Country [37]
0
0
China
Query!
State/province [37]
0
0
Suzhou
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Angers
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
La Tronche
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Lille Cedex
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Nice
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Paris
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Pierre Benite
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Toulouse Cedex 09
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Berlin
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Chemnitz
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Duesseldorf
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Halle (Saale)
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Hamburg
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Köln
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Mainz A. Rhein
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Muenster
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Ulm
Query!
Country [54]
0
0
Greece
Query!
State/province [54]
0
0
Athens
Query!
Country [55]
0
0
Greece
Query!
State/province [55]
0
0
Patras
Query!
Country [56]
0
0
Greece
Query!
State/province [56]
0
0
Thessaloniki
Query!
Country [57]
0
0
Israel
Query!
State/province [57]
0
0
Halfa
Query!
Country [58]
0
0
Israel
Query!
State/province [58]
0
0
Jerusalem
Query!
Country [59]
0
0
Israel
Query!
State/province [59]
0
0
Petah Tikva
Query!
Country [60]
0
0
Israel
Query!
State/province [60]
0
0
Ramat Gan
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Avellino
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Bologna
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Brescia
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Cuneo
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Firenze
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Milano
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Monza
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Napoli
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Pavia
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Roma
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Salerno
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
San Giovanni Rotondo
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Torino
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Torrette Di Ancona
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Udine
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Akita-shi
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Anjo
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Chiba-Shi
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Fukushima-shi
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Isehara-shi
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Kanazawa-shi
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Kobe-shi
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Kumamoto-shi
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Kurashiki-shi
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Minato-ku
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Okayama-shi
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Osaka-shi
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Osakasayama-shi
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Sapporo-shi
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Suita-shi
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Sunto-gun
Query!
Country [92]
0
0
Japan
Query!
State/province [92]
0
0
Tsukuba-shi
Query!
Country [93]
0
0
Japan
Query!
State/province [93]
0
0
Wakayama-shi
Query!
Country [94]
0
0
Korea, Republic of
Query!
State/province [94]
0
0
Goyang-si
Query!
Country [95]
0
0
Korea, Republic of
Query!
State/province [95]
0
0
Seoul
Query!
Country [96]
0
0
Korea, Republic of
Query!
State/province [96]
0
0
Suwon
Query!
Country [97]
0
0
Netherlands
Query!
State/province [97]
0
0
Groningen
Query!
Country [98]
0
0
Netherlands
Query!
State/province [98]
0
0
Maastricht
Query!
Country [99]
0
0
Poland
Query!
State/province [99]
0
0
Gdansk
Query!
Country [100]
0
0
Poland
Query!
State/province [100]
0
0
Warszawa
Query!
Country [101]
0
0
Spain
Query!
State/province [101]
0
0
Barcelona
Query!
Country [102]
0
0
Spain
Query!
State/province [102]
0
0
Granada
Query!
Country [103]
0
0
Spain
Query!
State/province [103]
0
0
L'Hospitalet de Llobregat
Query!
Country [104]
0
0
Spain
Query!
State/province [104]
0
0
Madrid
Query!
Country [105]
0
0
Spain
Query!
State/province [105]
0
0
Majadahonda
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
Malaga
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Oviedo
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Palma de Mallorca
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Pamplona
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Salamanca
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
San Sebastian
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Sevilla
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Valencia
Query!
Country [114]
0
0
Sweden
Query!
State/province [114]
0
0
Huddinge
Query!
Country [115]
0
0
Sweden
Query!
State/province [115]
0
0
Lund
Query!
Country [116]
0
0
United Kingdom
Query!
State/province [116]
0
0
Bristol
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Glasgow
Query!
Country [118]
0
0
United Kingdom
Query!
State/province [118]
0
0
London
Query!
Country [119]
0
0
United Kingdom
Query!
State/province [119]
0
0
Manchester
Query!
Country [120]
0
0
United Kingdom
Query!
State/province [120]
0
0
Nottingham
Query!
Country [121]
0
0
United Kingdom
Query!
State/province [121]
0
0
Sutton
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Wirral
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Alexion Pharmaceuticals, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of
ravulizumab in adult and adolescent participants with hematopoietic stem cell
transplant-associated thrombotic microangiopathy (HSCT-TMA). In Stage 1, an open-label,
single-arm period, the dosing regimen will be confirmed. In Stage 2, participants will be
randomized to receive either blinded ravulizumab plus best supportive care or matching
placebo plus best supportive care. The treatment period is 26 weeks (open-label for Stage 1,
and randomized, double-blind, and placebo-controlled for Stage 2) followed by a 26-week
follow-up period.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04543591
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Alexion Pharmaceuticals, Inc. (Sponsor)
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-855-752-2356
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04543591
Download to PDF